Recommended Topic Related To:

Antizol

"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...

Antizol

Indications
Dosage
How Supplied

INDICATIONS

Antizol (fomepizole) is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION).

DOSAGE AND ADMINISTRATION

Treatment Guidelines: If ethylene glycol or methanol poisoning is left untreated, the natural progression of the poisoning leads to accumulation of toxic metabolites, including glycolic and oxalic acids (ethylene glycol intoxication) and formic acid (methanol intoxication). These metabolites can induce metabolic acidosis, nausea/vomiting, seizures, stupor, coma, calcium oxaluria, acute tubular necrosis, blindness, and death. The diagnosis of these poisonings may be difficult because ethylene glycol and methanol concentrations diminish in the blood as they are metabolized to their respective metabolites. Hence, both ethylene glycol and methanol concentrations and acid base balance, as determined by serum electrolyte (anion gap) and/or arterial blood gas analysis, should be frequently monitored and used to guide treatment.

Treatment consists of blocking the formation of toxic metabolites using inhibitors of alcohol dehydrogenase, such as Antizol (fomepizole) , and correction of metabolic abnormalities. In patients with high ethylene glycol or methanol concentrations ( ≥ 50 mg/dL), significant metabolic acidosis, or renal failure, hemodialysis should be considered to remove ethylene glycol or methanol and the respective toxic metabolites of these alcohols.

Treatment with Antizol (fomepizole) : Begin Antizol (fomepizole) treatment immediately upon suspicion of ethylene glycol or methanol ingestion based on patient history and/or anion gap metabolic acidosis, increased osmolar gap, visual disturbances, or oxalate crystals in the urine, OR a documented serum ethylene glycol or methanol concentration greater than 20 mg/dL.

Hemodialysis: Hemodialysis should be considered in addition to Antizol (fomepizole) in the case of renal failure, significant or worsening metabolic acidosis, or a measured ethylene glycol or methanol concentration of greater than or equal to 50 mg/dL. Patients should be dialyzed to correct metabolic abnormalities and to lower the ethylene glycol concentrations below 50 mg/dL.

Discontinuation of Antizol (fomepizole) Treatment: Treatment with Antizol (fomepizole) may be discontinued when ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH.

Dosing of Antizol (fomepizole) : A loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter until ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH. All doses should be administered as a slow intravenous infusion over 30 minutes (see Administration).

Dosage with Renal Dialysis: Antizol® (fomepizole) Injection is dialyzable and the frequency of dosing should be increased to every 4 hours during hemodialysis.

Antizol (fomepizole) Dosing in Patients Requiring Hemodialysis

DOSE AT THE BEGINNING OF HEMODIALYSIS
   If <6 hours since last Antizol dose    If ≥ 6 hours since last Antizol dose
   Do not administer dose    Administer next scheduled dose
DOSING DURING HEMODIALYSIS
   Dose every 4 hours
DOSING AT THE TIME HEMODIALYSIS IS COMPLETED
Time between last dose and the end of hemodialysis  
   <1 hour Do not administer dose at the end of hemodialysis
   1–3 hours Administer 1/2 of next scheduled dose
   >3 hours Administer next scheduled dose
MAINTENANCE DOSING OFF HEMODIALYSIS
   Give next scheduled dose 12 hours from last dose administered

Administration: Antizol (fomepizole) solidifies at temperatures less than 25°C (77°F). If the Antizol (fomepizole) solution has become solid in the vial, the solution should be liquefied by running the vial under warm water or by holding in the hand. Solidification does not affect the efficacy, safety, or stability of Antizol (fomepizole) . Using sterile technique, the appropriate dose of Antizol (fomepizole) should be drawn from the vial with a syringe and injected into at least 100 mL of sterile 0.9% sodium chloride injection or dextrose 5% injection. Mix well. The entire contents of the resulting solution should be infused over 30 minutes. Antizol (fomepizole) , like all parenteral products, should be inspected visually for particulate matter prior to administration.

Stability: Antizol (fomepizole) diluted in 0.9% sodium chloride injection or dextrose 5% injection remains stable and sterile for at least 24 hours when stored refrigerated or at room temperature. Antizol (fomepizole) does not contain preservatives. Therefore, maintain sterile conditions, and after dilution do not use beyond 24 hours. Solutions showing haziness, particulate matter, precipitate, discoloration, or leakage should not be used.

HOW SUPPLIED

Antizol (fomepizole) is supplied as a sterile, preservative-free solution for intravenous use as:

Supplied in packages of four vials. Each vial contains 1.5 mL (1 g/mL) of fomepizole.

NDC 68727-200-02

Store at controlled room temperature, 20° to 25°C (68° to 77°F)

Distributed by: Jazz Pharmaceuticals, Inc. Palo Alto, CA 94304. For questions of a medical nature, call 1-888-867-7426. Revision Date: April 2006. FDA Rev date: 12/8/2000

Last reviewed on RxList: 11/6/2008
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.